HOME >> MEDICINE >> NEWS
12-month study demonstrated tolerability and efficacy of Daytrana

SAN DIEGO MAY 23, 2007 Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced that DAYTRANATM (methylphenidate transdermal system), the first and only non-oral medication approved for treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children aged 6 to 12 years, provided significant improvement in symptom control and tolerability, according to results of a 12-month open-label study presented at the American Psychiatric Association (APA) annual meeting in San Diego.

"We documented that children with ADHD experienced effective ADHD treatment with use of DAYTRANA for 12 months, sustaining the improvements in their ability to maintain focus and concentration," said investigator Oscar Bukstein, M.D., M.P.H ,Associate Professor of Psychiatry, University of Pittsburgh School of Medicine. "More importantly, Daytrana maintained a favorable safety profile, meeting the study's primary endpoint, and demonstrating an incidence of adverse events that is consistent with previous trials and other stimulants in this class."

Shire's DAYTRANA is the first and only patch medication approved by the U.S. Food and Drug Administration (FDA) to treat the symptoms of ADHD in children aged 6 to 12 years. DAYTRANA is available in four dosage strengths 10 mg, 15 mg, 20 mg and 30 mg all designed for once-daily use. When worn for the recommended nine hours, efficacy has been demonstrated from the first time point measured (two hours) through the 12-hour time point. Because DAYTRANA is a patch, physicians may recommend that patients shorten the wear time if shorter duration of effect is desired or to help manage the potential for late-day side effects.

Bukstein added, "DAYTRANA's novel patch delivery system offers physicians and parents of children with ADHD a convenient, non-oral option to individualize ADHD treatment to meet their children's changing schedules."

This study was an open-label extension of four clinical trials. T
'"/>

Contact: Marion E. Glick
212-601-8273
Porter Novelli
23-May-2007


Page: 1 2 3

Related medicine news :

1. $1.5 billion needed to ensure 12-month stockpile of pediatric vaccines
2. Childhood obesity indicates greater risk of school absenteeism, Penn study reveals
3. Penn study finds pro-death proteins required to regulate healthy immune function
4. New study shows promise in reducing surgical risks associated with surgical bleeding
5. New study counts the economic cost of persistent pain in Australia
6. UCLA researchers awarded $9M contract for study identifiying antibiotic treatment for MRSA
7. Most seniors now have drug coverage, U-M study shows
8. To gain muscle and lose fat, drink milk: study
9. Wheres the beef? Not enough of it is on elders plates, muscle-metabolism study suggests
10. Even older women at high risk have little interest in being tested for HIV, study finds
11. Metabolic study in mice could lead to good cholesterol boosters

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: month study demonstrated tolerability and efficacy Daytrana

(Date:8/30/2015)... West Hempstead, NY (PRWEB) , ... August 31, ... ... system installer Total Security Integrated Systems announces specific strategies to help assisted living ... well as their grounds from break-ins and theft. According to security experts at ...
(Date:8/30/2015)... , ... August 30, 2015 , ... ... joined the company as the new Global Communications Director for InHealth Media. ... experience having spent the last 16 years doing on-air television, producing shows, on ...
(Date:8/30/2015)... Rosa, CA (PRWEB) , ... August 30, 2015 ... ... Intensity Focused Ultrasound (HIFU) medical devices for the treatment of prostate cancer, has ... – introduced this summer at the treatment center in Puerto Vallarta, Mexico. , ...
(Date:8/29/2015)... , ... August 29, 2015 , ... ... of two inventors from Miller Place, N.Y. "I specialize in manual therapy, and ... In addition, it can be used for additional muscle dysfunction throughout the body." ...
(Date:8/29/2015)... , ... August 29, 2015 , ... Next weekend is ... summer (which astronomically, officially ends on September 22nd this year). For IT security personnel, ... hangovers linger on which could prove far more costly than a simple headache. , ...
Breaking Medicine News(10 mins):Health News:Total Security Announces Security Systems Tips for New York Assisted Living Facilities and Nursing Homes 2Health News:Total Security Announces Security Systems Tips for New York Assisted Living Facilities and Nursing Homes 3Health News:InHealth Media Appoints New Global Communications Director 2Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4
(Date:8/28/2015)... Research and Markets ( ... "Investigation Report on China,s Ranibizumab Market, 2012-2019" report ... was approved by CFDA to treat wet age- related ... product of Novartis, is available in the Chinese market. ... drug for the treatment of wet AMD in ...
(Date:8/28/2015)... Company plc ("Perrigo") (NYSE: PRGO ; TASE) today ... OTC brands from GSK in an all cash transaction ... demonstration of Perrigo,s unique ability to maximize brand value ... countries.  Perrigo Chairman, President and CEO ... to complete this transaction, which clearly demonstrates our ability ...
(Date:8/28/2015)... PUNE, India , August 28, 2015 ... Essential Oils), Livestock (Pork/Swine, Poultry, Ruminant, and Aquaculture), & by ... , Asia-Pacific , and Rest of ... by MarketsandMarkets, The global market for Eubiotics was valued at ... USD 7.05 Billion by 2020, at a CAGR of 7.4% ...
Breaking Medicine Technology:Investigation Report on China's Ranibizumab Market, 2012-2019 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5
Cached News: